skip to main content
X

Industries

Health Care

Trust our extensive advisory, audit, and tax services experience in the health care industry to provide you with a customized winning strategy that helps you thrive, and ensures your long-term survival and success.

DOES THE PFIZER RESTRUCTURING MAKE SENSE?

July 26, 2018

DOES THE PFIZER RESTRUCTURING MAKE SENSE?

The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer.

Pfizer recently announced a major restructuring into three business segments. The move followed an unsuccessful attempt by the company to market its OTC, or Consumer Healthcare segment as it will be named under the new regime. The reorganization will position the company’s most promising growth area as its rebranded Innovative Medicines segment with the existing business lines from the old segment, as well as adding biosimilars and a new hospital business unit.

The Established Medicine segment will include many of its legacy products, including Lipitor. Management indicates that this segment will operate as a standalone business and include drugs whose patent rights will expire soon along with other legacy products, as well as having its own dedicated manufacturing capabilities.

While positioned as a standalone, this segment could be on “life support” as the continued ability to extend the life of certain formulations (Lipitor, Viagra) will be tested and will likely face more competition from generics. The restructuring leads to the question of whether this segment will be sold or spun-off along with the Consumer Healthcare segment.

The Innovative Medicines segment, which by all reading represents the future growth potential of Pfizer, includes many of the formulations currently on the market for internal medicines — Elequis and Lyrica, to oncology formulations such as Ibrance and Xtandi and inflammation and immunology drugs, including Enbrel and Xeijanz. The segment will now include biosimilars and a new business unit specializing in anti-infectives and sterile injectables, according to Pfizer.

On the surface, Consumer Healthcare may not be compatible with the core business, with approximately $3.4B in revenue its size is less than 10% of total revenues. Management could consider acquisitions in this space, but it would take away funds to consummate a merger of a larger pharma or acquire a smaller research firm. Does the Consumer Healthcare segment have the draw to attract a buyer or would such an acquisition strategy work?

The situation brings to mind a similar situation from a few years earlier. In 2013, Pfizer announced a restructuring into 3 business segments — two of which were labeled Innovative business lines and the remaining the Value business line. Interestingly, consumer healthcare was included in one of the Innovative business segments. In 2016, Pfizer considered a break-up in the wake of its failure to acquire Allergan. Restructuring is not a new idea, but one that will keep resurfacing until a mega-merger such as an Allergan or Bristol-Myers-Squibb occurs, where the combined firms can restructure (read sell or spin-off) the less desirable segments.

If Management can execute a sale of Consumer Healthcare and either sell or spin-off the Established Medicines segment, we see a company that will have the capital to pursue research-oriented firms and their portfolios, or craft the mega-merger they have sought so intensely. If the sale of both segments occurs this may increase the risk of ownership of Pfizer stock, as some earnings insulation from these segments will not be available.  

Click here to read the entire article originally published on PharmExec.com.

Hide Firm Disclaimer

©2020 UHY LLP. ALL RIGHTS RESERVED.

UHY LLP is a licensed independent CPA firm that performs attest services in an alternative practice structure with UHY Advisors, Inc. and its subsidiary entities. UHY Advisors, Inc. provides tax and business consulting services through wholly owned subsidiary entities that operate under the name of "UHY Advisors." UHY Advisors, Inc. and its subsidiary entities are not licensed CPA firms. UHY LLP and UHY Advisors, Inc. are U.S. members of Urbach Hacker Young International Limited, a UK company, and form part of the international UHY network of legally independent accounting and consulting firms. "UHY" is the brand name for the UHY international network. Any services described herein are provided by UHY LLP and/or UHY Advisors (as the case may be) and not by UHY or any other member firm of UHY. Neither UHY nor any member of UHY has any liability for services provided by other members.

On this website, (i) the term "our firm", "we" and terms of similar import, denote the alternative practice structure conducted by UHY LLP and UHY Advisors, Inc. and its subsidiary entities, and (ii) the term "UHYI" denotes the UHY international network, in each case as more fully described in the preceding paragraph.